Across TCGA pan-cancer cohorts, RGPD2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RGPD2 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RGPD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RGPD2 expression acts as an unfavorable survival marker.

BRCA and SKCM are the cancer types where RGPD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.336	0.924	<.001	24	view →
SKCM	OS	Median	II,III,IV	0.245	0.731	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RGPD2 tumor-vs-normal RNA expression · all RGPD2 data types